Overview

Multiple Ascending Dose Study of Miravirsen in Treatment-Naïve Chronic Hepatitis C Subjects

Status:
Completed
Trial end date:
2011-12-01
Target enrollment:
Participant gender:
Summary
The main purpose of this study is to determine the safety and tolerability of multiple dosing of miravirsen in subjects infected with chronic hepatitis C. Secondary purpose includes assessment of pharmacokinetics of miravirsen and assessment of miravirsen's effect on HCV viral titer.
Phase:
Phase 2
Details
Lead Sponsor:
Santaris Pharma A/S